1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow aflibercept 8 mg: new trials by email Literature Review of aflibercept 8 mg trials Research Report on aflibercept 8 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-12-24 | 2026-02-05 |
| A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration QL1207H injection, Aflibercept 8 mg - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 356 | 2026-03-01 | 2026-03-24 |
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) Aflibercept 8 mg - Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 1126 | 2024-07-24 | 2026-09-18 |
Polypoidal Choroidal Vasculopathy (1)
Qilu Pharmaceutical Co., Ltd. (1) · Regeneron Pharmaceuticals (1) · Yeungnam University College of Medicine (1)
Puerto Rico (1) · South Korea (1) · United States (1)